The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
Author:
Funder
Novo Nordisk
AstraZeneca
Boehringer Ingelheim
Publisher
Elsevier BV
Subject
Pharmacology
Reference103 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
2. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015;Global Burden of Disease Liver Cancer;JAMA Oncol.,2017
3. Hepatocellular carcinoma in cirrhosis: incidence and risk factors;Fattovich;Gastroenterology,2004
4. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma;Massoud;Clin. Liver Dis.,2018
5. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma;Ronnebaum;Hepat. Oncol.,2022
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!;Expert Opinion on Pharmacotherapy;2024-01-29
2. SGLT2i Impact on HCC Incidence in Patients with Fatty liver disease and Diabetes: A Nation-wide Cohort Study in South Korea;2024-01-23
3. Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-01
4. Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches;International Journal of Molecular Sciences;2023-09-28
5. The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?;American Journal of Cardiovascular Drugs;2023-09-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3